Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasm characterized by constitutive activation of extracellular signal-regulated kinase (ERK). Genomic characterization has identified activating point mutations including mutually exclusive BRAFV600E and activating MAP2K1 mutations to be responsible for ERK activation in a majority of pediatric LCH patients. Here, we report the discovery of a novel BRAF kinase fusion, PACSIN2-BRAF, in a child with multisystem LCH. This is the second reported case of an activating BRAF kinase fusion and indicates a recurrent pathologic mechanism. Genomic evaluation for activating kinase fusions should be strongly considered in pediatric LCH patients lacking more common mutations.
INTRODUCTION
Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasm characterized by clonal proliferation of CD1a + /CD207 + cells. 1 At a molecular level, pathologic constitutive activation of extra- patients, respectively. 4, 8, 9 There are also case reports of mutations in ARAF 10 and ERBB3, 4 a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, in pediatric LCH.
A recent report identified a single case of an in-frame BRAF kinase fusion (FAM73A-BRAF) in a child with LCH. 11 Due to the limited mRNA sequencing (RNA-seq) of LCH to date, however, it is unclear if fusions in BRAF or other kinases are recurrent in pediatric LCH. Here, we report the discovery of a novel BRAF kinase fusion, PACSIN2-BRAF, produced by chromosomal translocation t(22;7)(q13.2;q34) in a child with refractory cutaneous LCH. This is the first report of this fusion in human disease and represents the second reported kinase fusion in a child with LCH. This finding suggests that in-frame activating BRAF kinase fusions are a recurrent phenomenon in pediatric LCH and a recurrent genomic mechanism for ERK activation in patients without BRAFV600E activating mutations.
METHODS
Parent-informed consent and patient-informed assent were obtained for photographic documentation of the patient's skin lesions for clinical use and in a deidentified manner to report this case. Assent and consent were obtained for enrollment on specimen acquisition and molec- 
Case description and experimental results
At disease presentation, our patient was a healthy 6-year-old male child with no significant personal or family medical history. He developed a physically detectable right temporal bone lesion, further visualized by computed tomography (CT) scan (Fig. 1A) . He also presented with several 5-8 mm erythematous papular skin lesions on his trunk (Fig. 1B) . Upon resection, the temporal bone lesion consisted of CD1a + /CD207 + cells, consistent with a diagnosis of LCH (Fig. 1C) .
The cutaneous lesions were positive for CD1a and phospho-ERK1/2 (pERK1/2) and negative for BRAFV600E by immunohistochemistry (Fig. 1D ). This child's LCH was classified as multisystem (cutaneous, temporal bone), risk-organ negative (no bone marrow, liver, or spleen involvement) with a central nervous system (CNS)-risk lesion (temporal bone; CNS-risk lesions are a specific group of craniofacial bones, including the temporal bone, whose involvement is associated with increased risk of developing diabetes insipidus [DI]). 12 The patient was treated according to the LCH-III protocol 13 with routine extent of disease evaluations including brain magnetic resonance imagings and dermatology assessments.
After 12 weeks of therapy with prednisone and vinblastine (LCH-III, initial course 1, 2 13 ), the patient had persistent cutaneous lesions. To assess for refractory disease, a biopsy from two representative lesions was performed. Pathologic assessment confirmed active LCH with residual immunoreactivity for CD1a and pERK1/2 (Fig. 1E) . In order to identify a potential genetic alteration responsible for ERK activation, genomic DNA from these lesions underwent targeted mutational analysis using Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT), a hybrid capturebased DNA sequencing assay of 410 cancer genes (Supplementary Methods S1). 14 . 16 This assay evaluates for fusions across 35 cancer-related genes involved in chromosomal rearrangements. The BRAF-specific primers provide coverage for exons 7, 9, and 11. Using this method, we identified a novel BRAF fusion, PACSIN2-BRAF ( Fig. 2A) , generated through an in-frame fusion between genes PACSIN2 exon 7 (NM_001184970) on chromosome 22q13.2 and BRAF exon 9 (NM_004333) on chromosome 7q34. Although low tumor purity in the skin biopsy sample precluded detection of the fusion by genomic DNA mutational analysis, high expression of the fusion RNA transcript allowed for its detection by Archer FusionPlex.
As with other previously described BRAF fusions, this fusion produces a protein lacking the N-terminal regulatory RAS-binding domain of BRAF, thereby placing the BRAF kinase domain under aberrant regulation of the PACSIN2 promoter. PACSIN2 is an F-BAR protein involved in regulating EGFR signaling by mediating intracellular receptor trafficking. 17 Of particular importance here, deletion of the C-terminal SRC homology 3 (SH3) domain of PACSIN2 by itself has also been suggested to lead to ERK activation. 17 To evaluate the functional effects of PACSIN2-BRAF and the potential contribution of truncated PACSIN2 to ERK activation, we generated cDNA for both the PACSIN2-BRAF fusion and PACSIN2 cDNA truncated at exon 7 to mimic the portion of PACSIN2 incorporated in the fusion (Supplementary Methods S1). Stable expression of PACSIN2-BRAF, along with an empty vector, truncated PACSIN2 (exons 1-7), or BRAFV600E in GP2-293 cells revealed activation of MEK1/2 and ERK1/2 phosphorylation by both PACSIN2-BRAF and BRAFV600E (Fig. 2B ) concomitant with reduced phosphorylation of AKT1/2. Consistent with this, stable expression of PACSIN2-BRAF or BRAFV600E resulted in cytokine-independent growth of Ba/F3 cells (Fig. 2C), indicating that the PACSIN2-BRAF fusion is an activating event with pathway activity similar to the BRAFV600E mutation. PACSIN2-BRAF expression also sensitized Ba/F3 cells to MEK inhibition by cobimetinib but not to RAF inhibition by vemurafenib in vitro ( Fig. 2D; Supplementary Methods S1). Given that our patient's cutaneous lesions remain asymptomatic, and he has no evidence of DI or multisystem disease, we are monitoring his disease with careful surveillance rather than second-line or investigational therapy. As with previously reported BRAF fusions and based on our in vitro kinase inhibitor evaluation, his activating fusion is not expected to be sensitive to RAF inhibitors vemurafenib or dabrafenib but may be sensitive to MEK inhibitors trametinib or cobimetinib. 11, 15, 18, 19 
DISCUSSION
Chromosomal rearrangements have not been frequently reported in LCH. In fact, prior to the wider implementation of NGS, a study of 31 patient samples found no detectable translocations. 20 The discovery of this BRAF kinase fusion highlights fusions of BRAF as a recurrent alternative mechanism for pathologic ERK activation in LCH. Given these data and the discovery of recurrent fusions in anaplastic lymphoma kinase (ALK) and neurotrophic receptor tyrosine kinase (NTRK) members in non-LCH, 15 we suspect activating kinase fusions may have a higher prevalence in pediatric LCH. Genomic evaluation for activating kinase fusions should be strongly considered in pediatric LCH patients who do not have activating point mutations in BRAF, MAP2K1, or other genes known to be affected by coding nucleotide mutations in order to identify potential candidates for targeted therapeutics.
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